Crystal form of niroxostat dihydrobromide and preparation method and application thereof

CN120813574APending Publication Date: 2025-10-17CRYSTAL PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202480011398.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-16
Filing Date
2024-03-06
Publication Date
2025-10-17

AI Technical Summary

Technical Problem

In the existing technology, the most stable crystalline form A of nirostat dihydrobromide has low solubility, which affects the clinical efficacy of the drug and the processing during the production process.

Method used

New crystal forms CSV and CSVI were discovered and prepared. Based on the characteristic peaks of Cu-Kα radiation X-ray powder diffraction pattern and thermal analysis pattern, they were prepared using mixed solvents of ethers and acids or alcohol solvents to improve the solubility of the drugs. , compressibility and stability.

Benefits of technology

The new crystal forms CSV and CSVI have higher solubility, density and compressibility, which significantly improve the bioavailability and production efficiency of drugs, ensure the stability and quality consistency of drugs under different conditions, and reduce the cost during preparation processing. risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120813574A_ABST
    Figure CN120813574A_ABST
Patent Text Reader

Abstract

The invention relates to a novel crystal form of niroxostat dihydrobromide and a preparation method thereof, a pharmaceutical composition containing the crystal form, and application of the crystal form in preparation of gamma secretase inhibitor drugs and drugs for treating sclerofibroma.
Need to check novelty before this filing date? Find Prior Art

Description

Crystal form of nirostat dihydrobromide, preparation method and use thereof Technical Field

[0001] The present invention relates to the field of crystal chemistry, and in particular to a crystal form of nirostat dihydrobromide, a preparation method thereof, and uses thereof. Background Art

[0002] Desmoid tumors, also known as aggressive fibromatosis, are rare, locally aggressive, slow-growing soft tissue tumors. Although considered benign because they cannot metastasize, desmoid tumors can still cause serious complications and occasionally death in patients, necessitating an urgent need for treatment.

[0003] Surprisingly, the γ-secretase inhibitor nirogacestat, developed by SpringWorks Therapeutics, has been marketed in the US for the treatment of desmoid tumors. Nirogacestat binds to γ-secretase, blocking the hydrolytic activation of the Notch receptor. Existing clinical research data indicates that Notch signaling plays a crucial role in cancer development. Therefore, inhibiting Notch signaling is an important strategy for the treatment of desmoid tumors.

[0004] The chemical name of nirostat is (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide (hereinafter referred to as "Compound I"). The structural formula of Compound I dihydrobromide is as follows:

[0005] In small molecule drug development, drug polymorphism is a common phenomenon and a significant factor affecting drug quality. Crystals are solids whose compound molecules are arranged in an orderly three-dimensional microstructure, forming a lattice. Polymorphism refers to the phenomenon of a single compound existing in multiple crystalline forms. A compound may exist in one or more crystalline forms, but their existence and properties cannot be precisely predicted.

[0006] Different solid forms of active pharmaceutical ingredients (APIs) have varying physicochemical properties, including chemical stability and solubility, which may lead to varying dissolution and absorption of the drug in the body, thereby impacting the drug's clinical efficacy to a certain extent. Furthermore, different solid forms of active pharmaceutical ingredients (APIs) have varying manufacturability, including compressibility, milling properties, and stability to pressure during tableting, which may impact the processing of the active pharmaceutical ingredient during production. Therefore, different solid forms of an active pharmaceutical ingredient may have distinct characteristics, providing opportunities to improve drug performance.

[0007] Prior art WO2021029854A1 discloses multiple crystalline forms of Compound I dihydrobromide. According to Example 6 of WO2021029854A1, Form A is the most stable and preferred crystalline form. However, the inventors of the present application found that Form A has low solubility.

[0008] In order to find a new solid form that can improve the performance of drugs, the inventors of the present application unexpectedly discovered the new crystalline form of Compound I dihydrobromide provided by the present invention, which has advantages in at least one aspect of solubility, hygroscopicity, purification effect, stability, adhesion, compressibility, flowability, in vitro and in vivo dissolution, and bioavailability, especially high solubility, high density, good compressibility and good stability, which solves the problems existing in the prior art and is of great significance to the development of drugs containing Compound I dihydrobromide.

[0009] Summary of the Invention

[0010] The present invention provides a new crystal form of compound I dihydrobromide, a preparation method thereof, and a pharmaceutical composition containing the new crystal form.

[0011] According to the purpose of the present invention, the present invention provides a crystalline form CSV of the dihydrobromide salt of Compound I (hereinafter referred to as "crystalline form CSV").

[0012] On the one hand, using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form CSV has characteristic peaks at diffraction angles 2θ of 6.1°±0.2°, 9.6°±0.2°, and 13.6°±0.2°.

[0013] Further, using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form CSV has characteristic peaks at one, two, or three of the diffraction angles 2θ of 4.5±0.2°, 16.1°±0.2°, and 18.6°±0.2°; preferably, the X-ray powder diffraction pattern of the crystalline form CSV has characteristic peaks at diffraction angles 2θ of 4.5±0.2°, 16.1°±0.2°, and 18.6°±0.2°.

[0014] Further, using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form CSV has characteristic peaks at one, two, or three of the diffraction angles 2θ of 12.7±0.2°, 21.5°±0.2°, and 23.0°±0.2°; preferably, the X-ray powder diffraction pattern of the crystalline form CSV has characteristic peaks at diffraction angles 2θ of 12.7±0.2°, 21.5°±0.2°, and 23.0°±0.2°.

[0015] On the other hand, using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form CSV has characteristic peaks at any three, or four, or five, or six, or seven, or eight, or nine of the diffraction angle 2θ values ​​of 6.1°±0.2°, 9.6°±0.2°, 13.6°±0.2°, 4.5±0.2°, 16.1°±0.2°, 18.6°±0.2°, 12.7±0.2°, 21.5°±0.2°, and 23.0°±0.2°.

[0016] Without limitation, using Cu-Kα radiation, the X-ray powder diffraction pattern of Form CSV is substantially as shown in FIG1 .

[0017] Without limitation, the TGA graph of Form CSV is substantially as shown in FIG2 , and when heated to about 100° C., it exhibits a weight loss of about 0.04%.

[0018] Without limitation, the DSC graph of the crystalline form CSV is substantially as shown in FIG3 , which has an endothermic peak with an onset temperature of about 259° C. and a peak temperature of about 263° C.

[0019] Without limitation, Form CSV is an anhydrate.

[0020] According to the purpose of the present invention, the present invention also provides a method for preparing the crystalline form CSV, the preparation method comprising:

[0021] The dihydrobromide solid of Compound I is dissolved in a mixed solvent of ether and acid, evaporated to obtain a solid, and the obtained solid is heated to obtain the crystalline form CSV.

[0022] The crystalline CSV provided by the present invention has the following unexpected technical effects:

[0023] (1) Compared with the prior art, the crystalline CSV provided by the present invention has superior compressibility. The good compressibility of the crystalline CSV can effectively improve problems such as substandard hardness / friability and tablet cracking during tableting, making the formulation process more reliable, improving product appearance, and enhancing product quality and production efficiency.

[0024] (2) Compared with the prior art, the crystalline form CSV provided by the present invention has a higher density. Experimental results show that the bulk density and tap density of the crystalline form CSV of the present invention are superior to those of the prior art form A. The high density of the crystalline form CSV is conducive to large-scale production, can reduce dust, and reduce occupational hazards.

[0025] (3) The crystalline CSV provided by the present invention has good stability.

[0026] Crystalline CSV maintained its crystal form unchanged and its purity remained essentially unchanged for at least six months under conditions of 25°C / 60% RH and 40°C / 75% RH. It also maintained its crystal form unchanged and its purity remained essentially unchanged for at least two months under conditions of 60°C / 75% RH. This demonstrates that crystalline CSV exhibits excellent stability under long-term, accelerated, and even more stringent conditions.

[0027] Crystalline CSV exhibits excellent mechanical stability. After grinding and exposure to varying degrees of pressure, the crystal form of CSV remains unchanged.

[0028] High humidity conditions caused by seasonal variations, regional climate differences, and environmental factors can affect the storage, transportation, and production of APIs. Furthermore, APIs often require grinding or pulverization during the pharmaceutical manufacturing process. The excellent stability of the CSV crystal form helps prevent the effects of crystal transformation during storage, transportation, and production on drug quality. It also reduces the risk of API crystallinity loss and crystal transformation during pharmaceutical manufacturing. This ensures consistent and controllable API quality and minimizes variations in drug quality, bioavailability, and toxic side effects caused by changes in crystal form.

[0029] According to the purpose of the present invention, the present invention provides a crystalline form CSVI of the dihydrobromide salt of Compound I (hereinafter referred to as "crystalline form CSVI").

[0030] On the one hand, using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form CSVI has characteristic peaks at diffraction angles 2θ of 8.8°±0.2°, 10.4°±0.2°, 19.4°±0.2°, and 20.9°±0.2°.

[0031] Furthermore, using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form CSVI has characteristic peaks at one, two, or three of the diffraction angles 2θ of 22.9°±0.2°, 26.8°±0.2°, and 25.9°±0.2°; preferably, the X-ray powder diffraction pattern of the crystalline form CSVI has characteristic peaks at diffraction angles 2θ of 22.9°±0.2°, 26.8°±0.2°, and 25.9°±0.2°.

[0032] On the other hand, using Cu-Kα radiation, the X-ray powder diffraction pattern of the crystalline form CSVI has characteristic peaks at any 4, or 5, or 6, or 7, or 8, or 9 of the diffraction angle 2θ values ​​of 8.8°±0.2°, 10.4°±0.2°, 19.4°±0.2°, 20.9°±0.2°, 22.9°±0.2°, 26.8°±0.2°, 25.9°±0.2°, 6.3°±0.2°, and 12.7°±0.2°.

[0033] Without limitation, using Cu-Kα radiation, the X-ray powder diffraction pattern of Form CSVI is substantially as shown in FIG. 7 , FIG. 8 , or FIG. 10 .

[0034] Without limitation, the TGA graph of Form CSVI is substantially as shown in FIG9 , which has a mass loss of about 1.1% when heated to about 80° C. and a mass loss of about 0.6% from about 80° C. to about 110° C.

[0035] Without limitation, the crystalline form CSVI is a hydrate, more preferably a 0.25 hydrate.

[0036] According to the purpose of the present invention, the present invention also provides a method for preparing the crystalline form CSVI, the preparation method comprising:

[0037] The dihydrobromide salt of Compound I was dissolved in an alcohol solvent and filtered. Toluene was added to the filtrate, and the mixture was allowed to stand at -20°C to precipitate a solid. The solid was separated, dried under vacuum, and the crystalline form CSVI was obtained.

[0038] Furthermore, the alcohol solvent is preferably methanol; the volume ratio of the alcohol solvent to toluene is preferably 1:5; and the drying temperature is preferably room temperature-80°C.

[0039] The crystalline form CSVI provided by the present invention has the following unexpected technical effects:

[0040] (1) Compared to the prior art, the crystalline form CSVI provided by the present invention has higher solubility. Nirorestat is a poorly water-soluble drug belonging to BCS II. Compared to the prior art form A, the crystalline form CSVI has higher solubility in FaSSIF and FeSSIF, which is beneficial for improving drug absorption in the human body and enhancing bioavailability.

[0041] (2) Compared with the prior art, the crystalline CSVI provided by the present invention has superior compressibility. The improved compressibility of crystalline CSVI can effectively improve problems such as substandard hardness / friability and tablet cracking during tableting, making the formulation process more reliable, improving product appearance, and enhancing product quality and production efficiency.

[0042] (3) The crystalline form CSVI provided by the present invention has good stability.

[0043] Crystalline CSVI maintained its crystalline form for at least eight months at 25°C / 60% RH and 40°C / 75% RH, and for at least two months at 60°C / 75% RH. This indicates that crystalline CSVI exhibits excellent stability under long-term, accelerated, and more stringent conditions.

[0044] Crystalline CSVI exhibits excellent mechanical stability. After grinding and exposure to varying degrees of pressure, the crystal form of CSVI remains unchanged.

[0045] High humidity conditions caused by seasonal variations, regional climate differences, and environmental factors can affect the storage, transportation, and production of APIs. Furthermore, APIs often require grinding or pulverization during the pharmaceutical manufacturing process. The excellent stability of the CSVI crystal form helps prevent the effects of crystal transformation during storage, transportation, and production, while also reducing the risk of API crystallinity loss and crystal transformation during pharmaceutical manufacturing. This ensures consistent and controllable API quality and minimizes variations in drug quality, bioavailability, and toxic side effects caused by changes in crystal form.

[0046] According to the purpose of the present invention, the present invention provides a pharmaceutical composition, which comprises an effective therapeutic amount of crystalline form CSV, crystalline form CSVI, or any mixture of the above two crystalline forms and pharmaceutically acceptable excipients.

[0047] According to the purpose of the present invention, the present invention provides use of the crystalline form CSV, the crystalline form CSVI or any mixture of the two crystalline forms above in the preparation of a γ-secretase inhibitor drug.

[0048] According to the purpose of the present invention, the present invention provides the use of the crystal form CSV, the crystal form CSVI or any mixture of the above two crystal forms in the preparation of a drug for treating desmoid tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 is the XRPD pattern of crystalline form CSV

[0050] Figure 2 is the TGA graph of crystal form CSV

[0051] Figure 3 is the DSC graph of crystal form CSV

[0052] Figure 4 is a comparison of XRPD patterns of CSV before and after storage under different conditions (from top to bottom: before storage, after 6 months at 25°C / 60% RH, after 6 months at 40°C / 75% RH, and after 2 months at 60°C / 75% RH)

[0053] Figure 5 is an XRPD stack of the crystalline form CSV before and after tableting (from top to bottom: before tableting, after 5kN tableting, after 10kN tableting, after 20kN tableting)

[0054] Figure 6 is an XRPD overlay of the CSV crystal before and after ball milling (from top to bottom: before ball milling, after ball milling)

[0055] Figure 7 is the XRPD pattern of crystalline form CSVI

[0056] Figure 8 is the XRPD pattern of crystalline form CSVI

[0057] Figure 9 is the TGA graph of crystal form CSVI

[0058] Figure 10 is the XRPD pattern of crystalline form CSVI

[0059] Figure 11 is a comparison of XRPD patterns of crystalline form CSVI before and after storage under different conditions (from top to bottom: before storage, after storage at 25°C / 60% RH for 8 months, after storage at 40°C / 75% RH for 8 months, and after storage at 60°C / 75% RH for 2 months)

[0060] Figure 12 is an XRPD stack of crystalline form CSVI before and after tableting (from top to bottom: before tableting, after 5kN tableting, after 10kN tableting, after 20kN tableting)

[0061] Figure 13 is an XRPD stack of crystal form CSVI before and after ball milling (from top to bottom: before ball milling, after ball milling) DETAILED DESCRIPTION

[0062] The present invention is described in detail with reference to the following examples, which describe in detail the preparation and use of the crystalline forms of the present invention. It will be apparent to those skilled in the art that many variations in both materials and methods may be made without departing from the scope of the present invention.

[0063] The abbreviations used in the present invention are explained as follows:

[0064] XRPD: X-ray powder diffraction

[0065] DSC: Differential Scanning Calorimetry

[0066] TGA: Thermogravimetric analysis

[0067] 1 H NMR: liquid hydrogen nuclear magnetic spectroscopy

[0068] HPLC: High Performance Liquid Chromatography

[0069] FeSSIF: fed state simulated intestinal fluid

[0070] FaSSIF: Fasted State Simulated Intestinal Fluid

[0071] RH: relative humidity

[0072] RT: room temperature

[0073] Instruments and methods used to collect data:

[0074] The X-ray powder diffraction patterns of the present invention were collected on a Bruker D8 ADVANCE X-ray powder diffractometer. The X-ray powder diffraction method parameters are as follows:

[0075] X-ray source: Cu, Kα

[0076] 1.54060; 1.54439

[0077] Kα2 / Kα1 intensity ratio: 0.50

[0078] Voltage: 40kV

[0079] Current: 40mA

[0080] Scanning range: from 4.0 to 40.0 degrees.

[0081] The differential scanning calorimetry (DSC) diagrams of the present invention were collected on a TA Q2000. The DSC method parameters of the present invention are as follows:

[0082] Scan rate: 10℃ / min

[0083] Shielding gas: N2

[0084] The thermogravimetric analysis (TGA) graphs of the present invention were collected on a TA Q500. The TGA method parameters of the present invention are as follows:

[0085] Scan rate: 10℃ / min

[0086] Shielding gas: N2

[0087] The nuclear magnetic resonance hydrogen spectrum data of the present invention ( 1 H NMR spectra were obtained on a Bruker Avance II DMX 400M HZ nuclear magnetic resonance spectrometer. 1-5 mg of sample was weighed and dissolved in 0.5 mL of deuterated dimethyl sulfoxide to prepare a 2-10 mg / mL solution.

[0088] The purity test method of the present invention is shown in Table 1.

[0089] Table 1

[0090] The test method for dynamic solubility of the present invention is shown in Table 2.

[0091] Table 2

[0092] The "evaporation" is accomplished by conventional methods in the art, such as slow evaporation or fast evaporation. Slow evaporation involves sealing the container with a sealing film, puncturing a hole, and allowing the container to evaporate; fast evaporation involves leaving the container open for evaporation.

[0093] The vacuum drying is performed using conventional methods in the art. The drying temperature can be room temperature or higher, preferably from room temperature to about 60°C, or to 50°C, or to 40°C. The drying time can be 2-48 hours, or overnight. Vacuum drying is typically performed in a vacuum oven containing a cup of water.

[0094] The “characteristic peak” refers to a representative diffraction peak used to identify crystals. When tested using Cu-Kα radiation, the peak position can usually have an error of ±0.2°.

[0095] The "anhydrous substance" refers to a solid substance that does not contain crystal water or crystallization solvent.

[0096] The "hydrate" refers to a solid substance containing water of crystallization.

[0097] In the present invention, "crystals" or "crystal forms" can be characterized by X-ray powder diffraction. Those skilled in the art will appreciate that X-ray powder diffraction patterns can vary depending on instrument conditions, sample preparation, and sample purity. The relative intensities of diffraction peaks in an X-ray powder diffraction pattern may also vary with experimental conditions, so the diffraction peak intensities cannot be the sole or decisive factor in determining a crystal form. In fact, the relative intensities of diffraction peaks in an X-ray powder diffraction pattern are related to the preferred orientation of the crystal. The diffraction peak intensities shown herein are illustrative and not intended for absolute comparison. Therefore, those skilled in the art will appreciate that the X-ray powder diffraction patterns of the crystal forms claimed by the present invention do not necessarily have to be identical to those in the Examples described herein; any crystal form having an X-ray powder diffraction pattern with characteristic peaks identical or similar to those in these patterns falls within the scope of the present invention. Those skilled in the art can compare the X-ray powder diffraction patterns listed herein with those of an unknown crystal form to determine whether the two patterns reflect the same or different crystal forms.

[0098] In some embodiments, the crystalline form CSV or crystalline form CSVI of the present invention is pure and substantially free of any other crystalline form. As used herein, "substantially free" when referring to a new crystalline form means that the crystalline form contains less than 20% by weight of any other crystalline form, particularly less than 10% by weight of any other crystalline form, more particularly less than 5% by weight of any other crystalline form, and even more particularly less than 1% by weight of any other crystalline form.

[0099] The term "about" in the present invention, when used to refer to a measurable value, such as mass, time, temperature, etc., means that there is a certain floating range around the specific value, which can be ±10%, ±5%, ±1%, ±0.5%, or ±0.1%.

[0100] Unless otherwise specified, the following examples are all operated at room temperature, which is not a specific temperature value but refers to a temperature range of 10-30°C.

[0101] According to the present invention, the compound I as a raw material includes but is not limited to solid form (crystalline or amorphous), oily, liquid form and solution. Preferably, the compound I as a raw material is in solid form.

[0102] Compound I used in the following examples can be prepared according to existing technology, for example, according to the method described in WO2021029854A1.

[0103] Example 1 Preparation method of crystal form CSV

[0104] Approximately 85 mg of Compound I dihydrobromide solid was weighed into a vial, and 2.0 mL of a mixed solvent of 2-methyltetrahydrofuran / formic acid (v / v, 1:1) was added. After dissolution, the solution was filtered to obtain a clear solution. The resulting solution was evaporated at room temperature for about 3 days to obtain a solid. The resulting solid was heated to 160° C. under nitrogen protection, maintained at 160° C. for 10 minutes, and then returned to room temperature. It was then heated to 200° C. under nitrogen protection, maintained at 200° C. for 60 minutes, and then returned to room temperature to obtain a crystalline solid.

[0105] The obtained crystalline solid was tested to be the crystal form CSV of the present invention. Its X-ray powder diffraction pattern is shown in FIG1 , and the X-ray powder diffraction data are shown in Table 3.

[0106] The TGA graph of the crystalline form CSV is shown in FIG2 , and it exhibits a weight loss of approximately 0.04% when heated to approximately 100° C.

[0107] The DSC graph of the crystalline form CSV is shown in FIG3 , which has an endothermic peak with an onset temperature of about 259° C. and a peak temperature of about 263° C.

[0108] Table 3

[0109] Example 2 Compressibility of Crystalline Form CSV

[0110] The tablets were compressed using an ENERPAC manual tablet press. About 60 mg of the crystalline form CSV and the prior art form A sample were added to a Φ6 mm circular flat punch, compressed under a pressure of 3 kN, and placed at room temperature for 24 hours. After complete elastic recovery, the diameter (D) and thickness (L) of the tablets were measured using a vernier caliper, and the radial crushing force (hardness, H) was tested using a tablet hardness tester. The tensile strength of the powder was calculated using the formula T = 2H / πDL. The test results showed that the average tensile strength of the crystalline form CSV was 0.55 MPa, and the average tensile strength of the prior art form A was 0.37 MPa. Under a certain pressure, the greater the tensile strength, the better the compressibility. The results show that compared with the prior art form A, the crystalline form CSV has better compressibility.

[0111] Example 3 Density of Crystalline Form CSV

[0112] Gently put about 500 mg of sample into a 5 mL graduated cylinder to measure the volume before tapping. Then tap the powder 1250 times on a ZS-2E tapping instrument to make the powder in a tapped state. Measure the volume after tapping and calculate the bulk density ρ0 and tap density ρ f The density results of the crystal form CSV and the prior art form A are shown in Table 4, and the results show that the density of the crystal form CSV is better than that of the prior art form A.

[0113] Table 4

[0114] Example 4 Stability of Crystalline Form CSV

[0115] Appropriate amounts of crystalline CSV were sealed and placed under 25°C / 60% RH, 40°C / 75% RH, and 60°C / 75% RH, respectively. XRPD and HPLC were used to test the crystalline form and purity. The results are shown in Table 5, and the XRPD comparison chart is shown in Figure 4. The results show that crystalline CSV is stable for at least six months at 25°C / 60% RH and 40°C / 75% RH, demonstrating its good stability under both long-term and accelerated conditions. Furthermore, crystalline CSV is stable for at least two months at 60°C / 75% RH, demonstrating its excellent stability even under more stringent conditions.

[0116] Table 5

[0117] Example 5 Stability of Crystalline Form CSV under Mechanical Force

[0118] An appropriate amount of crystalline form CSV was taken and pressed into tablets using a Φ6 mm round flat punch at different pressures. XRPD tests were performed before and after tableting. The test results are shown in Table 6, and the XRPD comparison chart is shown in Figure 5. The results show that crystalline form CSV has good stability under different pressures.

[0119] An appropriate amount of crystalline CSV was ball-milled at 500 rpm for 5 minutes. XRPD analysis was performed before and after ball milling. The XRPD comparison chart is shown in Figure 6. The results show that the crystalline CSV remains unchanged before and after ball milling, and the crystalline CSV has good stability under mechanical force.

[0120] Table 6

[0121] Example 6 Preparation of Crystalline Form CSVI

[0122] 0.64 g of Compound I dihydrobromide was weighed and dissolved in 8 mL of methanol. 45 mL of toluene was added to the clear solution and magnetically stirred at -20°C for approximately 18 hours to precipitate a solid. The solid was then filtered at room temperature. The wet cake was dried at 35°C and then vacuum-dried at 80°C for approximately 9.5 hours to obtain a crystalline solid. Testing confirmed that the resulting crystalline solid was Form CSVI of the present invention. Its X-ray powder diffraction pattern is shown in Figure 7.

[0123] Example 7 Preparation of Crystalline Form CSVI

[0124] 200 mg of Compound I dihydrobromide solid was weighed and dissolved in 2.5 mL of methanol. 12.5 mL of toluene was added to the clear solution, and a small amount of seed crystals was added. The solution was allowed to stand at -20°C for approximately 16 hours to precipitate a solid, which was then filtered under vacuum at room temperature. The wet cake was dried at 25°C for approximately 4 hours, and then dried under vacuum at 70°C for approximately 6 hours to obtain a crystalline solid.

[0125] After testing, the obtained crystalline solid was found to be the crystal form CSVI of the present invention, and its X-ray powder diffraction pattern is shown in FIG8 .

[0126] The TGA graph of crystalline form CSVI is shown in FIG9 . When heated to 80° C., it has a mass loss of about 1.1%, and a mass loss of about 0.6% from 80° C. to 110° C., corresponding to 0.25 molar equivalents of crystalline water.

[0127] Crystal form CSVI 1 The H NMR data are: 1H NMR(400MHz,DMSO-d6)δ11.29(s,1H),9.30(brs,2H),7.93(brs,2H),7.75(s,1H),7.54(s, 1H),7.08(td,J=9.8,2.4Hz,1H),6.90(d,J=9.3Hz,1H),4.22(s,1H),3.51(s,2H),3.30-3.1 9 (m, 2H), 3.00-2.88 (m, 1H), 2.87-2.69 (m, 2H), 2.61-2.52 (m, 2H), 2.29-2.14 (m, 1H), 2.04-1.73 (m, 3H), 1.64 (d, J = 7.6 Hz, 6H), 1.41-1.25 (m, 2H), 0.91 (t, J = 7.3 Hz, 3H), 0.85 (s, 9H). NMR results showed that there was no residual crystalline CSVI.

[0128] Example 8 Preparation Method of Crystalline Form CSVI

[0129] 200 mg of Compound I dihydrobromide solid was weighed and dissolved in 2.5 mL of methanol. 12.5 mL of toluene was added to the clear solution, and a small amount of seed crystals was added. The solution was allowed to stand at -20°C for about 16 hours to precipitate a solid, which was then filtered at room temperature. The wet cake was dried at 25°C for about 4 hours, then dried under vacuum at 70°C for about 6 hours. The resulting solid was then cycled once at a relative humidity of 0%-60%-0% to obtain a crystalline solid.

[0130] After testing, the obtained crystalline solid was found to be the crystalline form CSVI of the present invention. Its X-ray powder diffraction pattern is shown in FIG10 , and the X-ray powder diffraction data are shown in Table 7.

[0131] Table 7

[0132] Example 9 Preparation Method of Crystalline Form CSVI

[0133] 0.1934 g of compound I dihydrobromide solid was weighed and dissolved in 2.5 mL of methanol. 12.5 mL of toluene was added to the clear solution and allowed to stand at -20°C for about 16 hours to precipitate a solid. The solution was then filtered with suction at room temperature. The wet cake was dried at 35°C for about 6 hours and then dried under vacuum at 60°C for about 3 hours to obtain a crystalline solid. The obtained crystalline solid was found to be Form CSVI of the present invention.

[0134] Example 10 Solubility of Crystalline Form CSVI

[0135] When conducting drug solubility testing to predict in vivo performance, it is crucial to closely mimic in vivo conditions. For orally administered drugs, FaSSIF and FeSSIF can simulate in vivo conditions and predict the effects of food ingestion. Solubility measurements in these media more closely resemble solubility in the human body.

[0136] Appropriate amounts of crystalline Form CSVI were dispersed in FaSSIF and FeSSIF at 37°C to prepare suspensions. After equilibration for 0.5 hours, the suspensions were filtered. The concentrations of Compound I (mg / mL) in the filtrates were determined by HPLC. The results are shown in Table 8. These results demonstrate that Form CSVI has higher solubility in FaSSIF and FeSSIF than Form A, a prior art form.

[0137] Table 8

[0138] Example 11 Compressibility of Crystalline Form CSVI

[0139] The tablets were compressed using an ENERPAC manual tablet press. About 60 mg of the crystalline form CSVI or the prior art form A sample was added to a Φ6 mm circular flat punch, compressed under a pressure of 3 kN, and placed at room temperature for 24 hours. After complete elastic recovery, the diameter (D) and thickness (L) of the tablets were measured using a vernier caliper, and the radial crushing force (hardness, H) was tested using a tablet hardness tester. The tensile strength of the powder was calculated using the formula T = 2H / πDL. The test results showed that the average tensile strength of the crystalline form CSVI was 0.907 MPa, and the average tensile strength of the prior art form A was 0.37 MPa. Under a certain pressure, the greater the tensile strength, the better the compressibility. The results show that compared with the prior art form A, the crystalline form CSVI has better compressibility.

[0140] Example 12 Stability of Crystalline Form CSVI

[0141] An appropriate amount of crystalline Form CSVI was sealed and placed at 25°C / 60% RH, 40°C / 75% RH, and 60°C / 75% RH, respectively. XRPD analysis was performed. The results are shown in Table 9, and a comparative XRPD plot is shown in Figure 11. These results demonstrate that Form CSVI is stable for at least eight months at both 25°C / 60% RH and 40°C / 75% RH, demonstrating its excellent stability under both long-term and accelerated conditions. Furthermore, Form CSVI remains stable for at least two months at 60°C / 75% RH, demonstrating its excellent stability even under more stringent conditions.

[0142] Table 9

[0143] Example 13 Stability of Crystalline Form CSVI under Mechanical Force

[0144] An appropriate amount of crystalline form CSVI was taken and pressed into tablets using a Φ6 mm round flat punch at different pressures. XRPD analysis was performed before and after tableting. The test results are shown in Table 10, and the XRPD comparison chart is shown in Figure 12. The results show that crystalline form CSVI has good stability under different pressures.

[0145] An appropriate amount of crystalline CSVI was ball-milled at 500 rpm for 5 minutes. XRPD analysis was performed before and after ball milling. The XRPD comparison chart is shown in Figure 13. The results show that the crystalline CSVI remains unchanged before and after ball milling, and the crystalline CSVI exhibits good stability under mechanical stress.

[0146] Table 10

[0147] The above embodiments are intended only to illustrate the technical concepts and features of the present invention. Their purpose is to enable those skilled in the art to understand the contents of the present invention and implement them accordingly. They are not intended to limit the scope of protection of the present invention. Any equivalent changes or modifications made in accordance with the spirit of the present invention are intended to be covered by the scope of protection of the present invention.

Claims

1. A crystalline form CSV of a dihydrobromide salt of Compound I, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic peaks at 2θ values ​​of 6.1°±0.2°, 9.6°±0.2°, and 13.6°±0.2°.

2. The crystalline form CSV of the dihydrobromide salt of Compound I according to claim 1, characterized in that Using Cu-Kα radiation, its X-ray powder diffraction pattern has a characteristic peak at at least one of 2θ values ​​of 4.5°±0.2°, 16.1°±0.2°, and 18.6°±0.2°.

3. The crystalline form CSV of the dihydrobromide salt of Compound I according to claim 1, characterized in that Using Cu—Kα radiation, its X-ray powder diffraction pattern has a characteristic peak at at least one of 2θ values ​​of 12.7°±0.2°, 21.5°±0.2°, and 23.0°±0.2°.

4. The crystalline form CSV of the dihydrobromide salt of Compound I according to claim 2, characterized in that: Using Cu—Kα radiation, its X-ray powder diffraction pattern has a characteristic peak at at least one of 2θ values ​​of 12.7°±0.2°, 25.1°±0.2°, and 23.0°±0.2°.

5. The crystalline form CSV of the dihydrobromide salt of Compound I according to claim 1, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern is basically as shown in Figure 1.

6. A crystalline form CSVI of dihydrobromide of Compound I, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern has characteristic peaks at 2θ values ​​of 8.8°±0.2°, 10.4°±0.2°, 19.4°±0.2°, and 20.9°±0.2°.

7. The crystalline form CSVI of the dihydrobromide salt of Compound I according to claim 6, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern has a characteristic peak at at least one of 2θ values ​​of 22.9°±0.2°, 26.8°±0.2°, and 25.9°±0.2°.

8. The crystalline form CSVI of the dihydrobromide salt of Compound I according to claim 6, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern is substantially as shown in FIG. 7 , FIG. 8 , or FIG. 10 .

9. A pharmaceutical composition comprising an effective therapeutic amount of the crystalline form CSV of the dihydrobromide salt of Compound I according to claim 1, the crystalline form CSVI of the dihydrobromide salt of Compound I according to claim 6, or any mixture of the two crystalline forms thereof, and a pharmaceutically acceptable excipient.

10. Use of the crystalline form CSV of the dihydrobromide salt of Compound I according to claim 1, the crystalline form CSVI of the dihydrobromide salt of Compound I according to claim 6, or any mixture of the two crystalline forms thereof in the preparation of a γ-secretase inhibitor drug.

11. Use of the crystalline form CSV of the dihydrobromide salt of Compound I according to claim 1, the crystalline form CSVI of the dihydrobromide salt of Compound I according to claim 6, or any mixture of the two crystalline forms thereof in the preparation of a drug for treating desmoid tumors.